Nomenclature
CAS number: 82413-20-5
3-[(1
E)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol; (
E)-α-[
p-[2-(dimethylamino)ethoxy]phenyl]-α′-ethyl-3-stilbenol; (
E)-1-[4′-(2-dimethylaminoethoxy)phenyl]-1-(3-hydroxyphenyl)-2-phenylbut-1-ene; 3-hydroxytamoxifen.
C
26H
29NO
2; mol wt 387.51.
C 80.59%, H 7.54%, N 3.61%, O 8.26%.
Description and references
Estrogen-receptor antagonist. Prepn: H. Schickaneder et al., EP 54168; eidem, US 5047431 (1982, 1991 both to Klinge); P. C. Ruenitz et al., J. Med. Chem. 25, 1056 (1982). Symposium
on pharmacology and clinical studies: Am.
J. Clin. Oncol. 14, Suppl. 2, S1-S63 (1991).
Clinical trial in breast cancer: P. F. Bruning, Eur. J. Cancer 28A, 1404 (1992).
Properties
Colorless crystals from ether, mp 162-163° (Schickaneder); also
reported as white crystals from benzene-hexane, mp 160-162° (Ruenitz).Derivative
Citrate.
Nomenclature
CAS number: 97752-20-0
K-21060E; FK-435.
C
26H
29NO
2.C
6H
8O
7; mol wt 579.64.
C 66.31%, H 6.43%, N 2.42%, O 24.84%.
Properties
Slightly sol in water, methanol, ethanol. Insol
in chloroform.Therapeutic Category
Antineoplastic (hormonal).
Keywords
Antineoplastic (Hormonal); Antiestrogens; Selective Estrogen Receptor Modulator (SERM)